The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors.
Lung cancer
follow-up
prognosis
surgical therapy
tumor marker
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
21
07
2021
revised:
18
08
2021
accepted:
15
08
2021
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
12
10
2021
Statut:
ppublish
Résumé
The aim of this study was to evaluate the utility of selected tumor markers for the detection of lung cancer recurrence during follow-up. The study group consisted of 109 patients and 109 healthy controls. The following biomarkers were selected: Carcinoembryonic antigen; cytokeratin fragment 19; neuron-specific enolase; tissue polypeptide-specific antigen; cytokeratin fragments 8, 18 and 19; insulin-like growth factor 1; pro-gastrin-releasing peptide; and 25-hydroxyvitamin D. The biomarkers were assessed individually or using a multivariate analysis. Carcinoembryonic antigen [area under the receiver operating characteristics curve (AUC)=0.6857, p<0.0001] and cytokeratin fragment 19 (AUC=0.6882, p<0.0001) proved best in detecting relapse. The multivariate model indicated insulin-like growth factor 1 (p=0.0006, AUC=0.6225) as the third most useful biomarker. The multivariate model using these three markers achieved the best AUC value of 0.7730 (p=0.0050). We demonstrated that carcinoembryonic antigen and cytokeratin fragment 19 play a key role in the detection of lung cancer recurrence. A multivariate approach can increase the effectiveness of detection.
Identifiants
pubmed: 34593462
pii: 41/10/5117
doi: 10.21873/anticanres.15328
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5117-5122Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.